Back to top

Image: Bigstock

Sarepta Therapeutics, Inc.

Read MoreHide Full Article

Sarepta third-quarter results were encouraging with the company reporting a narrower-than-expected loss. The company received a boost with the FDA granting accelerated approval to Exondys 51 for Duchenne muscular dystrophy (DMD).  The FDA approval makes Exondys 51 the first DMD treatment to gain approval in the U.S. Moreover, we are positive on the company’s strategic agreements to boost its DMD portfolio.  We are also encouraged by the company’s efforts in developing its DMD pipeline beyond Exondys 51 in other exon-skipping treatments. However, competition in the RNA-Based treatment market remains a threat. Also, dependence on a single product for near-term growth is concerning.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Sarepta Therapeutics, Inc. (SRPT) - free report >>